GENTIAL FAX GENTER

SEP 27 2006

BROWNRAYSMAN

BROWN RAYSMAN MILLSTEIN FELDER & STEINER W

FACSIMILE COVER SHEET

From:

Heidi Reese

Date:

September 27, 2006

Direct Dial:

(212) 895-2424

Client/Matter#:

6319-1815

PLEASE DELIVER AS SOON AS POSSIBLE TO:

Recipient

Mr. Brian Kwon, **PATENT EXAMINER**

Company

United States Patent &

Phone No.

571-272-0581

Fax No. 571-273-8300

Trademark Office

Total number of pages including this page:4. If you do not receive all the pages, please call (212) 895-2424.

Message:

We resubmit a copy of the Replacement Terminal Disclaimer originally mailed on 8/4/06 regarding:

Serial No.:

10/727,658

Filed:

December 5, 2003

Title:

Combinations of Potassium Channel Openers and Sodium Channel

Inhibitors or Sodium Channel -Influencing Active Compounds for

Treating Pains

Applicant:

Szelenyi et al.

Art Unit:

1614

Docket:

6319-1815

Our firm policy requires that this re-submission be duplicated by fax transmission.

PLEASE CONFIRM RECEIPT BY RETURN FACSIMILE.

Thank you.

Please Note: the information contained in this facsimile message is privileged and confidential, and is intended only for use of the individual named above and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, or if any problems occur with transmission, please notify sender or the mail room by telephone: (212) 895-2000. Thank You.

BROWN RAYSMAN MILLSTEIN FELDER & STEINER LLP

900 THIRD AVE NY NY 10022 T 212-895-2000 F 212 895-2900 brownraysman.com

SEP 2 7 2006

RE-SENT SEPT 26,2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Szelenyi et al.

Examiner:

Brian Kwon

Serial No.:

10/727,658

Art Unit:

1614

Filed:

December 5, 2003

Docket:

6319-1815 (formerly 034082-001)

Title:

Combinations of Potassium Channel Openers and Sodium Channel Inhibitors or

Sodium Channel -Influencing Active Compounds for Treating Pains

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

REPLACEMENT TERMINAL DISCLAIMER TRANSMITTAL

Sir:

As requested by the Examiner in a telephone call to the undersigned on July 24, 2006, enclosed herewith is a terminal disclaimer that replaces the terminal disclaimer which was filed April 3, 2006, in a response to the Office Action dated November 2, 2005. Applicants respectfully request that the enclosed terminal disclaimer be made of record in this application.

If additional fees are due, Applicants authorize the Commissioner to deduct said fees from deposit account number 02-4270.

Certificate of Mailing: I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First-Class Mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 4, 2006.

Kimberly Jones

Printed Name

Respectfully submitted,

Dated: 4 any Joob

Heidi Reese Reg. No. 57,841 BROWN RAYSMAN MILLSTEIN FELDER & STEINER LLP 900 Third Avenue New York, New York 10022 (212) 895-2000

Judi Reese

2004

SEP 2 7 2006

PTC/SB/25 (10-05)
Approved for use through 07/31/2006. QMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a varied OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a varied OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a varied OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION	6319-1815
In re Application of: SZELENYI et al.	
Application No.: 10/727,658	
Filed: December 5, 2003	
FOI: VALEANT PHARMACUETICALS INTERNATIONAL	
The owner*, VALEANT PHARMACUETICALS INTERNATIONAL. of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/727,658 filed on 10 December 5, 2003 as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner application are the stant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.	
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application;" In the event that: any such patent: granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
2. The undersigned is an attorney or agent of record. Reg. No. 57,841	
Heidi Reese	4 AUGUST 2001
- C Signature	
Heidi Reese Typed or printed name	
	212-895-2424 Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card information be included on this form. Provide credit card information and authorization of	on should not n PTO-2038.
*Statement under 37 CFR 3.73(b) Is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324. This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO Tomes) and 1.14. This collection is estimated to take 12 minutes to complete, to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, to process) an application from to the USPTO. Time will vary depending upon the individual case. Any comments on including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and I.A. Application of the USPTO. This Trademerk Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS Trademerk Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.	
Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	2

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.